In a significant move within the biotechnology sector, Regeneron Pharmaceuticals has agreed to purchase the gene-testing business of 23andMe for $256 million. This acquisition comes in the wake of 23andMe’s recent bankruptcy filing, driven by declining consumer demand and a major data breach that compromised sensitive genetic information.
Key takeaways
- Regeneron acquires 23andMe’s data bank containing DNA samples from over 15 million individuals.
- The deal is part of a bankruptcy auction process following 23andMe’s financial struggles.
- Regeneron commits to upholding 23andMe’s privacy policies and ensuring ethical use of genetic data.
- The transaction is expected to close in the third quarter of 2025.
Background on 23andMe’s challenges
23andMe, once a pioneer in the direct-to-consumer genetic testing market, has faced significant challenges in recent years. A data breach in 2023 severely impacted consumer trust and demand for its services. The breach exposed sensitive genetic and personal information of millions, prompting scrutiny from lawmakers and consumers alike.
In April 2025, 23andMe filed for bankruptcy, seeking to sell its business assets at auction. The company had previously built a substantial database of genetic information, which Regeneron now aims to leverage for its drug discovery initiatives.
Details of the acquisition
The acquisition deal, which was finalised through a bankruptcy auction, saw Regeneron outbid a nonprofit research institute founded by 23andMe’s co-founder Anne Wojcicki, which offered $146 million. Regeneron’s successful bid not only secures a vast repository of genetic data but also positions the company to enhance its capabilities in genomics-driven drug development.
As part of the agreement, Regeneron will acquire all of 23andMe’s business units, except for its telehealth service, Lemonaid Health, which is set to be discontinued. Following the acquisition, 23andMe will operate as a wholly owned subsidiary of Regeneron.
Commitment to data privacy
In light of the previous data breach, Regeneron has made a public commitment to uphold 23andMe’s existing privacy policies. The company has pledged to comply with all applicable data protection laws and to work transparently with an independent overseer appointed by the bankruptcy court. This overseer will assess the implications of the acquisition on consumer privacy and is expected to report back to the court by June 10, 2025.
Regeneron’s commitment to ethical data use is crucial, especially as concerns about genetic data privacy continue to grow. The company aims to reassure customers that their genetic information will be handled responsibly and securely.
Future implications
Analysts suggest that while the acquisition makes strategic sense for Regeneron, it may take years to realise a return on investment. The integration of 23andMe’s genetic data into Regeneron’s research and development processes could potentially lead to breakthroughs in personalised medicine and targeted therapies.
As the transaction moves towards completion, it highlights the ongoing evolution of the biotechnology landscape, where data privacy and ethical considerations are becoming increasingly paramount. The court is scheduled to review and potentially approve the transaction on June 17, 2025, marking a pivotal moment for both companies involved.
